English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut!
牛牛新股君
joined discussion · May 14 08:37

IPO News | “Helicobacter pylori new drug developer” DanNor Pharma-B launches its IPO, scheduled to list on May 22, with a minimum subscription amount of HKD 3,823.17

Futu Information reported on May 14 that $TENNOR THERAP-B (06872.HK)$ The company announced the IPO from May 14 to May 19, planning to globally offer approximately 8,280,600 shares, with an expected listing date of May 22.
Futu Information reported on May 14 that $TENNOR THERAP-B (06872.HK)$ The company announced the IPO from May 14 to May 19, planning to globally offer approximately 8,280,600 shares, with an expected listing date of May 22. Company Overview DanNor Pharma is a biotechnology company nearing commercialization, focusing on discovering, developing, and commercializing differentiated innovative drug products to address clinical needs in bacterial infections and bacterial metabolism-related diseases. With its multi-target conjugated molecule technology, the company is committed to providing patients with optimal treatment solutions to overcome limitations of traditional therapies and improve patient outcomes. The core product, Lifortonazole (TNP-2198), is the world’s first and, as of the latest practicable date, the only new molecular entity candidate drug targeting Helicobacter pylori infection since its discovery in 1982. The strategic partnerships established by the company with industry-leading enterprises fully demonstrate the therapeutic value and potential of Lifortonazole. Lifortonazole has received IND approval from both the National Medical Products Administration and the FDA and is currently under development in China and the United States. Financial Summary DanNor Pharma recorded net losses of RMB 191.8 million, RMB 145.9 million, and RMB 153.2 million in 2023, 2024, and 2025 respectively, primarily due to...
Company Overview
DanNor Pharma is a biotechnology company nearing commercialization, focusing on discovering, developing, and commercializing differentiated innovative drug products to address clinical needs in bacterial infections and bacterial metabolism-related diseases. With its multi-target conjugated molecule technology, the company is committed to providing patients with optimal treatment solutions to overcome limitations of traditional therapies and improve patient outcomes.
The core product, Lifotrizole (TNP-2198), is the world's first and, as of the latest practicable date, the only new molecular entity candidate drug in clinical development targeting Helicobacter pylori infection since its discovery in 1982. The strategic partnerships established with leading companies in the industry fully demonstrate the therapeutic value and potential of Lifotrizole. Lifotrizole has received IND approval from the National Medical Products Administration and the FDA, and is currently under development in both China and the United States.
Financial Summary
DanNor Pharma recorded net losses of RMB 191.8 million, RMB 145.9 million, and RMB 153.2 million in 2023, 2024, and 2025 respectively, primarily due to substantial research and development expenses incurred during the performance record period. In 2023, 2024, and 2025, the company's R&D expenditures were RMB 108.4 million, RMB 69.8 million, and RMB 71.9 million respectively.
Futu Information reported on May 14 that $TENNOR THERAP-B (06872.HK)$ The company announced the IPO from May 14 to May 19, planning to globally offer approximately 8,280,600 shares, with an expected listing date of May 22. Company Overview DanNor Pharma is a biotechnology company nearing commercialization, focusing on discovering, developing, and commercializing differentiated innovative drug products to address clinical needs in bacterial infections and bacterial metabolism-related diseases. With its multi-target conjugated molecule technology, the company is committed to providing patients with optimal treatment solutions to overcome limitations of traditional therapies and improve patient outcomes. The core product, Lifortonazole (TNP-2198), is the world’s first and, as of the latest practicable date, the only new molecular entity candidate drug targeting Helicobacter pylori infection since its discovery in 1982. The strategic partnerships established by the company with industry-leading enterprises fully demonstrate the therapeutic value and potential of Lifortonazole. Lifortonazole has received IND approval from both the National Medical Products Administration and the FDA and is currently under development in China and the United States. Financial Summary DanNor Pharma recorded net losses of RMB 191.8 million, RMB 145.9 million, and RMB 153.2 million in 2023, 2024, and 2025 respectively, primarily due to...
Use of Proceeds
In terms of funding use, DanNor Pharma expects the net proceeds from the global offering to be approximately HKD 558 million (assuming no exercise of the over-allotment option, at an offer price of HKD 75.70). According to the prospectus, DanNor Pharma intends to allocate the proceeds from the global offering for the following purposes:
Approximately 71% will be used for research, development, registration filing, and commercialization of the company's core products; about 7% will fund the planned Phase IIb MRCT for TNP-2092 oral formulation in treating HE, which the company anticipates will commence in the second half of 2027; around 7.3% will go towards the R&D of other candidate products; approximately 7.2% will be utilized for building the company’s own production plant in Zhongshan City, Guangdong Province; and roughly 7.5% will serve as working capital and for other general corporate purposes.
Further reading:Danno Pharmaceuticals-B Prospectus
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu Information reported on May 14 that $TENNOR THERAP-B (06872.HK)$ The company announced the IPO from May 14 to May 19, planning to globally offer approximately 8,280,600 shares, with an expected listing date of May 22. Company Overview DanNor Pharma is a biotechnology company nearing commercialization, focusing on discovering, developing, and commercializing differentiated innovative drug products to address clinical needs in bacterial infections and bacterial metabolism-related diseases. With its multi-target conjugated molecule technology, the company is committed to providing patients with optimal treatment solutions to overcome limitations of traditional therapies and improve patient outcomes. The core product, Lifortonazole (TNP-2198), is the world’s first and, as of the latest practicable date, the only new molecular entity candidate drug targeting Helicobacter pylori infection since its discovery in 1982. The strategic partnerships established by the company with industry-leading enterprises fully demonstrate the therapeutic value and potential of Lifortonazole. Lifortonazole has received IND approval from both the National Medical Products Administration and the FDA and is currently under development in China and the United States. Financial Summary DanNor Pharma recorded net losses of RMB 191.8 million, RMB 145.9 million, and RMB 153.2 million in 2023, 2024, and 2025 respectively, primarily due to...
Editor/Joe
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
8
54K Views
Report
Comments (2)
Write a Comment...
2
8
54